{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Herber CB"],"funding":["NIA NIH HHS","NIDDK NIH HHS","National Institutes of Health","National Institute on Aging"],"pagination":["44"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9036729"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["28(1)"],"pubmed_abstract":["Background
Menopausal hormone therapy (MHT) is recommended for only five years to treat vasomotor symptoms and vulvovaginal atrophy because of safety concerns with long-term treatment. We investigated the ability of 2',3',4'-trihydroxychalcone (2',3',4'-THC) to modulate estrogen receptor (ER)-mediated responses in order to find drug candidates that could potentially prevent the adverse effects of long-term MHT treatment.Methods
Transfection assays, real time-polymerase chain reaction, and microarrays were used to evaluate the effects of 2',3',4'-THC on gene regulation. Radioligand binding studies were used to determine if 2',3',4'-THC binds to ERα. Cell proliferation was examined in MCF-7 breast cancer cells by using growth curves and flow cytometry. Western blots were used"],"journal":["Molecular medicine (Cambridge, Mass.)"],"pubmed_title":["2',3',4'-Trihydroxychalcone changes estrogen receptor α regulation of genes and breast cancer cell proliferation by a reprogramming mechanism."],"pmcid":["PMC9036729"],"funding_grant_id":["1 R43 DK109862-01","1 R43 AG072965-01","R01 DK113019","R43 AG072965","R43 DK109862","DK113019-01A1"],"pubmed_authors":["Yuan C","Chang A","Wang JC","Cohen I","Leitman DC","Herber CB"],"additional_accession":[]},"is_claimable":false,"name":"2',3',4'-Trihydroxychalcone changes estrogen receptor α regulation of genes and breast cancer cell proliferation by a reprogramming mechanism.","description":"Background
Menopausal hormone therapy (MHT) is recommended for only five years to treat vasomotor symptoms and vulvovaginal atrophy because of safety concerns with long-term treatment. We investigated the ability of 2',3',4'-trihydroxychalcone (2',3',4'-THC) to modulate estrogen receptor (ER)-mediated responses in order to find drug candidates that could potentially prevent the adverse effects of long-term MHT treatment.Methods
Transfection assays, real time-polymerase chain reaction, and microarrays were used to evaluate the effects of 2',3',4'-THC on gene regulation. Radioligand binding studies were used to determine if 2',3',4'-THC binds to ERα. Cell proliferation was examined in MCF-7 breast cancer cells by using growth curves and flow cytometry. Western blots were used","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Apr","modification":"2026-06-01T02:00:22.549Z","creation":"2024-10-17T20:04:52.74Z"},"accession":"S-EPMC9036729","cross_references":{"pubmed":["35468719"],"doi":["10.1186/s10020-022-00470-z"]}}